Literature DB >> 32926151

Prospective observational study of respiratory Aspergillus colonization or disease in patients with various stages of chronic obstructive pulmonary disease utilizing culture versus nonculture techniques.

Sarmad Waqas1, Katie Dunne2, Alida Fe Talento2,3, Graham Wilson4, Ignacio Martin-Loeches1,5, Joseph Keane1,6, Thomas R Rogers2,3.   

Abstract

Chronic obstructive pulmonary disease (COPD) patients have been recognized to be at increased risk of Aspergillus spp. colonization, which may progress to invasive pulmonary aspergillosis (IPA). The objective of this study was to determine the frequency of Aspergillus colonization, or disease, in a cohort of COPD patients. A prospective observational study was undertaken to determine Aspergillus colonization, or disease, in consecutive COPD patients undergoing bronchoscopy. Fungal culture as well as galactomannan antigen (GM) and Aspergillus nucleic acid detection (PCR) were performed on bronchoalveolar lavage fluid (BAL) samples. One hundred and fifty patients were recruited. One hundred and twelve (74.7%) were outpatients, 38 (25.33%) were inpatients, of whom 6 (4%) were in the intensive care unit. Most patients (N = 122, 81.3%) were either COPD GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages 1 or 2. Nine (6%) patients were on systemic steroids, 64 (42.7%) on inhaled steroids, and 9 (6%) on both. Seventeen patients (11.3%) had at least one positive test for Aspergillus detection (culture ± galactomannan ± polymerase chain reaction [PCR]), 13 (76.4%) of whom were COPD GOLD stages 1 or 2.  Five patients had probable or putative IPA. Aspergillus sp. was detected in five patients (3.3%) by culture, but detection increased to 17 (11.3%) by the additional testing for GM or Aspergillus DNA. The frequency of Aspergillus detection in this cohort of COPD patients may reflect the predominance of early GOLD stages among the study population but deserves further investigation to determine its relevance as a predictive risk factor for IPA. LAY
SUMMARY: COPD is a risk factor for Aspergillus spp. colonization. Bronchoalveolar lavage samples of 150 COPD patients were tested for presence of Aspergillus fumigatus, which was detected in five patients (3.3%) by culture, but detection of Aspergillus increased to 17 (11.3%) by additional GM and PCR testing.
© The Author(s) 2020. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  Aspergillus; COPD; PCR; antigens; fungal; galactomannan; invasive pulmonary aspergillosis

Year:  2020        PMID: 32926151     DOI: 10.1093/mmy/myaa077

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  5 in total

Review 1.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

Review 2.  Impact of Lung Microbiota on COPD.

Authors:  Cristina Russo; Valeria Colaianni; Giuseppe Ielo; Maria Stella Valle; Lucia Spicuzza; Lucia Malaguarnera
Journal:  Biomedicines       Date:  2022-06-06

3.  Pulmonary aspergillosis and cryptococcosis as a complication of COVID-19.

Authors:  Edward C Traver; Melanie Malavé Sánchez
Journal:  Med Mycol Case Rep       Date:  2022-01-06

Review 4.  The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.

Authors:  Juan de Dios Caballero; Rafael Cantón; Manuel Ponce-Alonso; Marta María García-Clemente; Elia Gómez G de la Pedrosa; José Luis López-Campos; Luis Máiz; Rosa Del Campo; Miguel Ángel Martínez-García
Journal:  Microorganisms       Date:  2022-04-13

5.  Increased Incidence and Associated Risk Factors of Aspergillosis in Patients with Bronchiectasis.

Authors:  Bumhee Yang; Taehee Kim; Jiin Ryu; Hye Yun Park; Bin Hwangbo; Sun-Young Kong; Yong-Soo Kwon; Seung Jun Lee; Seung Won Ra; Yeon-Mok Oh; Jang Won Sohn; Kang Hyeon Choe; Hayoung Choi; Hyun Lee
Journal:  J Pers Med       Date:  2021-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.